Copyright © 2008 Published by Elsevier Masson SAS
ss="h4">Entendu et notxe9;
11<sup>esup> rxe9;union internationale sur le myxe9;lome, 25–30 juillet 2007, xee;le de Kos, Grxe8;ce
<span style='font-weight: bold'><span style='font-style: italic'>Results. –span>span> Acute toxicity was marked and included WHO grade III/IV mucositis (89%, 16%of them being grade IV), WHO grade III dermatitis (72%) and grade III/IV neutropenia (61%). This toxicity was significant but manageable with optimised supportive care, and never led to interruption of treatment for more than 1 week, although there were two toxic deaths. Complete global response rate at 6 months was 74%. Overall global survival at 1 and 2 years was 72%and 50%respectively, with a median follow-up of 17 months. Prognostic factors for overall survival were the Karnofsky index (71%survival at 3 years for patients with a Karnofsky index of 90–100%versus 30%for patients with a Karnofsky index of 80%versus 0%for patients with a Karnofsky index of 60-70%, <span style='font-style: italic'>p span>= 0.0001) and tumor location (55%at 3 years for oropharynx versus 37%for panpharynx versus 28%for hypopharynx, <span style='font-style: italic'>p span>= 0.009).
<span style='font-weight: bold'><span style='font-style: italic'>Conclusion. –span>span> These results confirm the efficacy of concomitant bid radiotherapy and chemotherapy in advanced unresectable tumor of the pharynx. The improvement in results will essentially depend on our capacity to restore in a good nutritional status the patients before beginning this heavy treatment.
style="float:right; padding-left:5px"> La Revue de Mxe9;decine Interne, Volume 28, Issue 10, October 2007, Pages 682-688 C. Hulin Abstract ss="mlktScroll"> style="line-height:150%"> ss="h3">Rxe9;sumxe9;ss="h4">ProposAprxe8;s des dxe9;cennies de progrxe8;s minimes, deux nouvelles classes mxe9;dicamenteuses avec de nouveaux mxe9;canismes d'action : immunomodulateurs (thalidomide et lxe9;nalidomide) et inhibiteur du protxe9;asome (bortxe9;zomib), ont montrxe9; une grande efficacitxe9; dans le traitement du myxe9;lome multiple. |
style="padding:3px 5px 0px 5px"> | science?_ob=RelatedArtURL&_udi=B6VMG-4S6GRG9-4&_orig=article&_acct=C000050221&_version=1&_userid=10&md5=e4368154c2ebc74015539e2cea282959">View More Related Articles |
11<sup>esup> rxe9;union internationale sur le myxe9;lome, 25–30 juillet 2007, xee;le de Kos, Grxe8;ce